SAN RAMON, Calif., May 18 /PRNewswire/ -- Breathe Technologies, Inc., a manufacturer of innovative technology solutions for people with respiratory conditions, including chronic obstructive pulmonary disease and sleep apnea, announced today it has secured $23 million in Series C financing. The financing was led by DAG Ventures and included Kleiner Perkins Caufield & Byers (KPCB), Delphi Ventures, Synergy Partners International and Johnson & Johnson Development Corporation. Additionally, industry leader John L. Miclot joined as chairman of the board, and the company received FDA 510(k) clearance for its wearable ventilation system.
"Our strong team of investors, the addition of John Miclot as chairman, and recent FDA clearance further validate that Breathe is well positioned to bring breakthrough solutions to the respiratory markets," said Gregory J. Kapust, president and CEO of Breathe Technologies. "The Series C financing will fund commercialization of Breathe's ultralight, mobile ventilation system for the millions of people worldwide with breathing challenges, such as COPD (chronic obstructive pulmonary disease). We will also continue development of our novel solutions for the sleep-disordered breathing market."
Chairman John Miclot, who was instrumental in building Respironics into a global leader in the sleep and respiratory markets, believes there is an extraordinary opportunity for innovation in the respiratory industry. "When I was introduced to Breathe's products and development plans, it was clear this company had great potential to dramatically alter this industry's landscape," stated Mr. Miclot, who became president and CEO